Intellia Therapeutics, Inc
Here’s whether Intellia Therapeutics, Inc (NTLA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.59% over 10 days); RSI 9 — oversold; weak 1-year return of -16.0%; 3-month momentum negative (-21.3%). Currently 62.0% off its 52-week high. Score: -7/7.
NTLA is trading below its 200-day MA ($13.40) — a key warning sign the longer-term trend is under pressure. An RSI of 9.5 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -16.0% compares to +16.5% for SPY (trailed the market by 32.5%). The current 62.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.